Lucid Diligence Brief: Telix / Regeneron radiopharma collaboration
Lucid Diligence Brief: Telix / Regeneron radiopharma collaboration Professional…
Public Health Today—March 20, 2026
This weekly public health update highlights recent developments across clinical…
ESGO 2026 Preview: Key Gynaecological Oncology Highlights to Watch
ESGO 2026 at a Glance Get ready for ESGO 2026. LucidQuest’s preview brings…
ECCO 2026 Preview: Key Crohn’s and Colitis Highlights to Watch
ECCO 2026 at a Glance Get ready for ECCO 2026. LucidQuest’s preview brings…
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in immuno-fibrotic disease space
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in…
Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics
Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics Professional…
Cardiovascular 2025 Review: From late rescue to earlier, smarter intervention
In 2025, cardiovascular medicine pivoted decisively toward earlier…
Rare Disease 2025 Review: From Orphan Innovation to a System-Level Stress Test
In 2025, rare disease innovation accelerated faster than the systems designed…
Immunology 2025 Review: From Mechanism Proliferation to Platform Discipline
In 2025, immunology moved from breadth to discipline: sharper focus on…
Endocrinology 2025 Review: Outcomes, Access, and Earlier Intervention
In 2025, endocrinology moved decisively toward outcomes that change long-term…
Hematology 2025 Review: Deeper Responses, Faster Translation, and the Push to Scale
The throughline of 2025 was not a single modality—it was the convergence of…
Respiratory 2025 Review: From Symptom Control to Disease Modification
In 2025, respiratory medicine crossed a threshold: biologics entered COPD at…